Form 4: Janux Therapeutics CEO Sells 25,000 Shares Under 10b5-1 Trading Plan

Janux Therapeutics CEO, David Alan Campbell, sold 25,000 shares of common stock at a weighted average price of $56.1922 per share, as part of a pre-arranged 10b5-1 trading plan.

Summary

• David Alan Campbell, the President and CEO of Janux Therapeutics, sold 25,000 shares of common stock on December 24, 2024.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 21, 2024.
• The weighted average sale price was $56.1922 per share, with individual prices ranging from $56.00 to $56.915.
• Following the transaction, Mr. Campbell directly owns 217,054 shares of Janux Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reports a routine stock sale by the CEO under a pre-arranged plan. It is neither particularly positive nor negative, and is a common practice.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, potentially impacting the stock price.

Industry Context

Executive stock sales are a common occurrence, and the use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading. This transaction is not unusual for a company of this size and stage.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the biotechnology sector like Janux Therapeutics.
• Similar transactions are regularly reported by executives at companies such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals.
• The sale of 25,000 shares is not unusual for an executive at a company of Janux's size and market capitalization.

Stakeholder Impact

• The sale may have a minor impact on shareholder sentiment, but is unlikely to cause a significant change in the stock price given the pre-planned nature of the transaction.

Key Dates

Keywords

Janux Therapeutics, David Alan Campbell, stock sale, Rule 10b5-1, insider trading, executive stock, share transaction